Japan works to shorten "drug lag," boost trials of new drugs.
Sinha
Gunjan
G
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000191:economics; D017277:Drug Approval; D004345:Drug Industry; D015507:Drugs, Investigational / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006077:Government Agencies; D006801:Humans; D033183:Interdisciplinary Communication; D007391:International Cooperation; D007564:Japan; D054547:National Cancer Institute (U.S.); D009316:National Institutes of Health (U.S.); D056687:Off-Label Use; D010348:Patient Care Team; D011640:Public Policy; D012108:Research Personnel / Q000193:education; D013997:Time Factors; D014481:United States
D000970:Antineoplastic Agents; D015507:Drugs, Investigational